VTGN
VistaGen Therapeutics, Inc.
There isn't enough reported data to score VTGN yet.
VTGN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
VTGN's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
VTGN PE Valuation
VTGN has no meaningful PE right now: it lost money over the past year.
VTGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect VTGN's losses to shrink, with revenue growing.
VTGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.66 | +$0.13 |
| Q1 2026 | -$1.83 | -$0.16 |
| Q4 2023 | -$3.53 | +$5.77 |
| Q3 2023 | -$4.81 | +$4.49 |
| Q2 2023 | -$6.55 | +$2.45 |
| Q1 2023 | -$8.61 | -$1.41 |
| Q4 2022 | -$9.30 | +$1.50 |
| Q3 2022 | -$9.30 | +$2.10 |
VTGN is still losing money, but far less than before: $1.66 per share over the past year, against $20.70 at its worst in late 2019.
VTGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.5M | +505% |
| Q4 2025 | $303K | +29% |
| Q3 2025 | $258K | +41% |
| Q2 2025 | $244K | +190% |
| Q4 2024 | $234K | -43% |
| Q3 2024 | $183K | -34% |
| Q1 2024 | $197.3K | +12% |
| Q1 2023 | $176K | +351% |
VTGN's revenue has grown year over year for five quarters in a row: $1M last quarter, up 505% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -904% | +5573 points |
| Q1 2026 | -3595% | N/A |
| Q4 2025 | -6451% | +11 points |
| Q3 2025 | -7772% | +1.8 points |
| Q2 2025 | -6477% | +7965 points |
| Q4 2024 | -6462% | -4545 points |
| Q3 2024 | -7774% | -5333 points |
| Q2 2024 | -14442% | N/A |
VTGN's operating margin was −904% last quarter, up 5573 points from the same quarter a year ago, near the top of its range since 2020.
VTGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$14.7M | +$4.1M |
| Q1 2026 | -$16.2M | -$6.1M |
| Q4 2025 | -$17.6M | -$7.4M |
| Q3 2025 | -$13.8M | -$2.9M |
| Q2 2025 | -$18.8M | -$8M |
| Q4 2024 | -$10.3M | -$5.7M |
| Q3 2024 | -$10.9M | -$4.7M |
| Q2 2024 | -$10.9M | -$3M |
VTGN has burned cash in almost every quarter: −$62M over the past year, against −$50M the year before.
VTGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +4.9M shares |
| 1 year | +35% | +11M shares |
| 3 years | +500% | +35.8M shares |
| 5 years | +783% | +38.1M shares |
| Available history | +2925% | +41.6M shares |
VTGN has 43M diluted shares, up 35% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
VTGN Net Leverage
VTGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VTGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 1.6 | Oversold |
VTGN's weekly RSI is 31 (neutral) and its Stochastic is 2 (oversold).
VTGN PE vs Healthcare Sector
VTGN has no meaningful PE right now: it lost money over the past year.
VTGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.21 | 14% below |
| 20 week MA | $0.23 | 22% below |
| 50 week MA | $0.61 | 70% below |
| 100 week MA | $1.79 | 90% below |
| 200 week MA | $2.90 | 94% below |
VTGN is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
VTGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.0 | $41.7 | +99% |
| 2021 | $41.7 | $60.9 | +46% |
| 2022 | $60.9 | $3.00 | -95% |
| 2023 | $3.00 | $5.14 | +71% |
| 2024 | $5.14 | $2.57 | -50% |
| 2025 | $2.57 | $0.73 | -72% |
| 2026 YTD | $0.73 | $0.18 | -75% |
VTGN has finished lower in three of the last six years. It's down 75% so far in 2026.